Physician profile
Renee Williams
NPI 1811938574
$37,714.84
in general payments reported to CMS, 2019-2025
11 companies · $9,045 in 2025
The $9,045 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.12 · 2020: $47.02 · 2021: $131 · 2022: $3,342 · 2023: $17K · 2024: $7,903 · 2025: $9,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $12K · Food and Beverage: $1,868 · Travel and Lodging: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,328.25 |
| Consulting Fee | $11,675.00 |
| Food and Beverage | $1,868.48 |
| Travel and Lodging | $1,311.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $14,142.14 | 2023-2024 | Gi Genius |
| Janssen Biotech, INC. | $10,017.67 | 2021-2025 | Stelara, Tremfya |
| Olympus America INC. | $6,665.05 | 2023-2025 | Evis Exera III Colonovideoscope, Evis Exera Lll Colonovideoscope |
| Pfizer INC. | $4,997.77 | 2025 | |
| Abbvie INC. | $1,086.83 | 2022-2024 | Rinvoq, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $245.19 | 2022-2024 | Entyvio |
| Exact Sciences Corporation | $202.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Cook Medical LLC | $180.95 | 2024 | Hemospray |
| Novo Nordisk INC | $96.11 | 2023 | |
| Boston Scientific Corporation | $56.32 | 2019-2022 | |
| Covidien LP | $24.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.